Tokyo, Aug. 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058705) titled 'An intervention study investigating the effect of high-amylose brown rice consumption on blood glucose levels and its long-term feasibility' on Aug. 5.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Open -no one is blinded Control - No treatment

Primary Sponsor: Institute - Ehime University

Condition: Condition - glucose abnormality Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Brown rice and high-amylose rice are thought to have beneficial effects on blood glucose levels. However, no studies have specifically investigated the effects of high-amylose brown rice on blood glucose. Brown rice tends to absorb water poorly and is harder to digest compared to white rice. When cooked in a regular rice cooker using the same method as for white rice, brown rice may not absorb enough water or gelatinize properly. This can make it harder and less sticky, and may also reduce its digestibility. Many foods show their health benefits only when eaten regularly over time. Therefore, in this study, participants were asked to cook and eat the rice in their usual home environment, using their own rice cookers and preferred methods. This approach allowed us to observe how people naturally prepared and ate the rice, and to identify cooking and eating methods that made the rice easier to consume. Based on this, the study aimed to examine the effects of high-amylose brown rice on blood glucose levels, and to explore how to make it more acceptable and easier to eat in daily life. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Daily consumption (equal to or more than 1 serving/day) of high-amylose brown rice (Hoshinishiki) for four weeks Interventions/Control_2 - Control

Eligibility: Age-lower limit - 40 years-old = Gender - Male and Female Key inclusion criteria - The persons aged 40-74 with HbA1c levels between 5.6% and 6.4%, based on a health checkup within the past year. Key exclusion criteria - 1. Under treatment for diabetes 2. Regularly visiting a doctor without physician's approval 3. Rice allergy 4. Deemed unsuitable by the principal investigator or collaborating physician Target Size - 30

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2025 Year 04 Month 24 Day Date of IRB - 2025 Year 07 Month 28 Day Anticipated trial start date - 2025 Year 08 Month 05 Day Last follow-up date - 2028 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067119

Disclaimer: Curated by HT Syndication.